Brii Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Brii Biosciences şirketinin toplam hissedar öz sermayesi CN¥2.8B ve toplam borcu CN¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla CN¥2.9B ve CN¥86.3M dir.

Anahtar bilgiler

Borç/özkaynak oranı

CN¥0

Borç

Faiz karşılama oranı	n/a
Nakit	CN¥2.39b
Eşitlik	CN¥2.81b
Toplam yükümlülükler	CN¥86.31m
Toplam varlıklar	CN¥2.90b

Son finansal sağlık güncellemeleri

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Nov 19

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Jul 26

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

Jan 12

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Sep 20

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Mar 24

Recent updates

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Nov 19

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Jul 26

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

Jan 12

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Sep 20

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Mar 24

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 2137 'nin kısa vadeli varlıkları ( CN¥2.6B ) kısa vadeli yükümlülüklerini ( CN¥67.7M ) aşıyor.

Uzun Vadeli Yükümlülükler: 2137 şirketinin kısa vadeli varlıkları ( CN¥2.6B ) uzun vadeli yükümlülüklerini ( CN¥18.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 2137 borçsuzdur.

Borcun Azaltılması: 2137 un 5 yıl önce borcu yoktu.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 2137 şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: 2137, serbest nakit akışı her yıl % 7.6 oranında tarihi oranda azalmaya devam ederse 3 yıldan fazla bir süre yeterli nakit akışına sahip olur

Brii Biosciences Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Recent updates

Co-founder recently bought HK$59k worth of stock

New major risk - Revenue and earnings growth

New major risk - Revenue size

Brii Biosciences Limited to Report First Half, 2024 Results on Aug 19, 2024

New minor risk - Market cap size

Brii Biosciences Limited Announces New Data from Two Phase 2 Studies Evaluating BRII-179

Brii Biosciences Limited, Annual General Meeting, Jun 25, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Brii Biosciences Limited to Report Fiscal Year 2023 Results on Mar 22, 2024

New minor risk - Profitability

Forecast to breakeven in 2026

Brii Biosciences (HKG:2137) Is In A Good Position To Deliver On Growth Plans

PBrii Biosciences Limited Presents New Data Highlighting Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting 2023

New minor risk - Share price stability

Consensus EPS estimates upgraded to CN¥0.92 loss

Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating Brii-179 (Vbi-2601) in Combination with Peg-Ifn for the Treatment of Chronic Hepatitis B

Consensus revenue estimates increase by 2,527%

First half 2023 earnings released: CN¥0.26 loss per share (vs CN¥0.48 loss in 1H 2022)

Brii Biosciences Limited to Report First Half, 2023 Results on Aug 22, 2023

Here's Why We're Not Too Worried About Brii Biosciences' (HKG:2137) Cash Burn Situation

Brii Biosciences Limited Announces Executive Changes

Shionogi Inc. entered into a definitive agreement to acquire Qpex Biopharma, Inc. from Brii Biosciences Limited (SEHK:2137) and Others for $140 million.

Brii Biosciences Limited Announces Dosing of First Subject in Phase 1 Clinical Trial Evaluating BRII-297

Consensus revenue estimates fall by 100%

Forecast breakeven date pushed back to 2025

Forecast to breakeven in 2024

Brii Biosciences Limited Announces Interim Findings from A Phase 2 Study

Companies Like Brii Biosciences (HKG:2137) Are In A Position To Invest In Growth

No longer forecast to breakeven

Brii Biosciences Limited Provides Update on Strategic Clinical Development Progress

High number of new directors

Brii Biosciences Announces New Data from Two Phase 1 Studies

Brii Biosciences Limited Announces Topline Results from a Phase 1 Study Evaluating its Long-Acting, Single-Injection Therapy, BRII-296, in the Development for the Treatment of Postpartum Depression

We're Hopeful That Brii Biosciences (HKG:2137) Will Use Its Cash Wisely

Brii Biosciences Limited Announces Executive Changes

Brii Biosciences Limited Announces Board and Committee Changes

Brii Biosciences Limited Announces Board Changes

Consensus forecasts updated

No longer forecast to breakeven

Brii Biosciences Limited Appoints Eleanor De Groot as Senior Vice President and Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Brii Biosciences Limited Appoints Eleanor De Groot as Chief Technology Officer and Aleksandar Skuban as Central Nervous System Diseases Therapy Area Head

Brii Biosciences Limited to Report First Half, 2022 Results on Aug 23, 2022

Brii Biosciences Announces Positive Data Demonstrating its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Live Omicron Virus BA.4/5 and BA.2.12.1 Subvariants

Brii Biosciences Appoints Dr. Susannah Cantrell as Chief Business Officer

Consensus revenue estimates increase by 14%

Brii Biosciences Limited Announces Commercial Launch of its Amubarvimab/Romlusevimab Combination Therapy for COVID-19 in China

Brii Biosciences Announces Positive Data from a Randomized, Single-Blind Study of its Long-Acting COVID-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, in China

Forecast to breakeven in 2023

Brii Bio Announces Positive Data Demonstrating Its Long-Acting Covid-19 Neutralizing Antibody Therapy, Amubarvimab/Romlusevimab Combination, Retains Neutralizing Activity Against Omicron Ba.2 Subvariant

No longer forecast to breakeven

Insufficient new directors

Brii Biosciences Limited Presents New Data on BRII-835 (VIR-2218) in Chinese Patients with Chronic Hepatitis B at APASL 2022

Brii Biosciences Limited, Annual General Meeting, Jun 22, 2022

Brii Biosciences Limited, Annual General Meeting, Jun 22, 2022

We're Not Worried About Brii Biosciences' (HKG:2137) Cash Burn

Brii Biosciences Limited to Report Fiscal Year 2021 Results on Mar 22, 2022

Brii Bio Appoints Karen D. Neuendorff as Chief People Officer and Head of Human Resources

Brii Biosciences Limited Doses First Patient in Phase 2a/2b Clinical Trial of BrII-179 (VBI-2601) for the Functional Cure of Chronic Hepatitis B

Brii Biosciences Limited Announces Amubarvimab/Romlusevimab Combination Retains Neutralizing Activity Against Omicron SARS-CoV-2 Variant

Brii Bio Announces Amubarvimab/Romlusevimab Combination Received Approval from NMPA as First COVID-19 Neutralizing Antibody Combination Therapy in China

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

Brii Biosciences Announces Completion of Enrollment in the Phase 3 National Institutes of Health ACTIV-2 Trial, Evaluating the BRII-196 and BRII-198 Monoclonal Neutralizing Antibody Combination for the Treatment of COVID-19

Brii Biosciences Limited has completed an IPO in the amount of HKD 2.482655 billion.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin